Edgar Filing: LA JOLLA PHARMACEUTICAL CO - Form 4

LA JOLLA Form 4 March 16, 2	PHARMACEUT	ICAL CO								
								OMB A	PPROVAL	
FORM	UNITED	STATES S		RITIES A			E COMMISSIO	N OMB Number:	3235-0287	
Check t if no lor subject Section Form 4 Form 5 obligati may cor <i>See</i> Inst	AENT OF rsuant to Se (a) of the Pt 30(h) o	ection 1 ublic U	SECUE 6(a) of th	Estimated burden hou response	Estimated average burden hours per response 0.5					
1(b).										
(Print or Type	Responses)									
1. Name and Address of Reporting Person <u>*</u> Gillespie Deirdre			2. Issuer Name and Ticker or Trading Symbol LA JOLLA PHARMACEUTICAL			5. Relationship of Reporting Person(s) to Issuer (Check all applicable)				
		(CO [LJ	PC]					-)	
(Last) (First) (Middle) 6455 NANCY RIDGE DRIVE			3. Date of Earliest Transaction (Month/Day/Year) 03/15/2006			_X_ Director10% Owner _X_ Officer (give titleOther (specify below) below) CEO				
(Street)			4. If Amendment, Date Original Filed(Month/Day/Year)			Applicable Line)	_X_Form filed by One Reporting Person			
SAN DIEC	GO, CA 92121						Form filed by Person	y More than One R	eporting	
(City)	(State)	(Zip)	Tab	le I - Non-I	Derivative	Securities	Acquired, Disposed	of, or Beneficia	lly Owned	
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)		Date, if	3. Transactio Code (Instr. 8) Code V	Disposed (Instr. 3,	l (A) or l of (D)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
Reminder: Re	port on a separate line	e for each clas	ss of sect	urities benet	Perso inforr requi	ons who re nation con red to resp ays a curre	or indirectly. espond to the collected tained in this form ond unless the for ently valid OMB co	m are not orm	SEC 1474 (9-02)	

 Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
 (e.g., puts, calls, warrants, options, convertible securities)

1. Title of	2.	3. Transaction Date 3A. I	Deemed 4.	5	5. Number of	6. Date Exercisable and	7. Title and Amount of
Derivative	Conversion	(Month/Day/Year) Exec	ution Date, if Tra	ansaction	Derivative	Expiration Date	Underlying Securities
Security	or Exercise	any	Co	ode S	Securities	(Month/Day/Year)	(Instr. 3 and 4)

Edgar Filing: LA JOLLA PHARMACEUTICAL CO - Form 4

(Instr. 3)	Price of Derivative Security		(Month/Day/Year)	(Instr.	8)	Acquired (A Disposed of (Instr. 3, 4, 5)	f (D)				
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	\$ 5.26	03/15/2006		А		800,000		(1)	03/15/2016	Common Stock	800,000

Reporting Owners

Relationships						
Director	10% Owner	Officer	Other			
Х		CEO				
		Director 10% Owner	Director 10% Owner Officer			

Signatures

/s/ Deirdre Y. Gillespie	03/16/2006			
<u>**</u> Signature of Reporting Person	Date			

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) The stock options vest and become exercisable with respect to 200,000 of the underlying shares on 3/15/2007. Thereafter, 1/36th of the remaining stock options vest and become exercisable each month until all options are vested.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.